SP70检测在良恶性胸腔积液鉴别诊断中的临床应用价值

目的：探讨 SP70检测在良恶性胸腔积液鉴别中的临床应用价值。方法选取2011年4月至2011年12月在我院就诊并经临床明确诊断为良性胸腔积液和恶性胸腔积液患者各90例，采集患者胸腔积液标本，检测 SP70、CEA、Cyfra21-1和 NSE 水平，并进行比较分析。结果恶性胸腔积液组患者 SP70、CEA、CYFRA21-1检测阳性率分别为72．2％、58．9％和53．3％，显著高于良性胸腔积液组的10．0％、13．3％和22．2％（P ＜0．05）；恶性胸腔积液组NSE 阳性率（31．1％）与良性胸腔积液组（20．0％）比较差异无统计学意义（P ＞0．05）。恶性胸腔积液组 SP70敏感度、特异度和符合率分别为72．2％、89．2％和81．6％，CEA 敏感度、特异度和符合率分别为58．9％、84．9％和74．2％，Cy-fra21-1敏感度、特异度和符合率分别为53．3％、67．1％和58．4％，NSE 敏感度、特异度和符合率分别为31．1％、78.0％和50．2％。两组患者血清 SP70检测率分别为5．6％、6．7％，差异无统计学意义（P ＞0．05），而胸腔积液 SP70检测率分别为10．0％、72．2％，差异具有统计学意义（P ＜0．05）。结论SP70对良、恶性胸腔积液的鉴别诊断具有着重要的临床价值和潜在的辅助作用，可为相关疾病的早期诊断和治疗提供有效信息。

The value of SP70 to differentiate benign and malignant pleural effusion

Objective To study the value of SP70 to differentiate benign and malignant pleural effusion.Methods Selected 90 cases of patients with benign pleural effusion and 90 cases of patients with malignant pleural effusion which were clinically diagnosed from April 2011 to December 2011 in our hospital,collected and comparative analysed the level of SP70、CEA、Cyfra21-1 and NSE.Results The positive rate of SP70,CEA,CYFRA21-1 in patients with malignant pleural effusions was 72.2% ,58.9%,53.3%,significantly higher than 10.0%,13.3%,22.2% in benign pleural effu-sion group （P 〈0.05）;NSE positive rate difference was not statistically significant （P〉0.05）in malignant pleural ef-fusion group （31.1%）and benign pleural effusion group （20.0%）.The sensitivity,specificity,coincidence rate of SP70 in patients with malignant pleural effusions was 72.2%,89.2%,81.6%,CEA was 58.9%,84.9%,74.2%,Cyfra 21-1 was 53.3%,67.1%,58.4%,NSE was 31.1%,78.0%,50.2%.The detection rates of serum SP70 in patients with be-nign and malignant pleural effusion was 5.6%,6.7%,the difference was not statistically significant （P〉0.05）,but in＆amp;nbsp;the pleural effusion was 10.0%,72.2% ,the difference was statistically significant （P 〈0.05）.Conclusion SP70 in the differential diagnosis of benign and malignant pleural effusion has an important clinical value,has a potential role in support for related diseases early diagnosis and treatment to provide valid information .